Nanotechnology-enabled delivery of NQO1 bioactivatable drugs

Journal of Drug Targeting

Volumn 23, Issue 7-8, 2015, Pages 672-680

  Ma, Xinpeng ^a,b   Moore, Zachary R ^a   Huang, Gang ^a   Huang, Xiumei ^a   Boothman, David A ^a   Gao, Jinming ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BIND Therapeutics   (United States)

Author keywords

Cancer targeting; drug delivery; nanoparticle; NQO1; prodrug; lapachone

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA LAPACHONE; NAD(P)H QUINONE OXIDOREDUCTASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; NANOPARTICLE; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; PRODRUG;

ANTINEOPLASTIC ACTIVITY; CIRCULATION TIME; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; MAXIMUM TOLERATED DOSE; MICELLE; NANOENCAPSULATION; NANOTECHNOLOGY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; ANIMAL; CHEMISTRY; DRUG DESIGN; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MAXIMUM TOLERATED DOSE; NAD(P)H DEHYDROGENASE (QUINONE); NANOPARTICLES; NANOTECHNOLOGY; NAPHTHOQUINONES; NEOPLASMS; PRODRUGS;

EID: 84944241741     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1073296     Document Type: Review

References (70)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29
2. Blanco E, Bey EA, Dong Y, et al. β-Lapachone-containing PEG- PLA polymer micelles as novel nanotherapeutics against NQO1- overexpressing tumor cells. J Control Release 2007;122:365-74
3. Blanco E, Bey EA, Khemtong C, et al. β-Lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 2010;70:3896-904
4. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009;234:123-31
5. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65: 36-48
6. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014;39:268-307
7. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128ra39
8. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24: 1029-46
9. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable longcirculating polymeric nanospheres. Science 1994;263:1600-3
10. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001;73:137-72
11. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80
12. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
13. Ross D, Kepa JK, Winski SL, et al. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129: 77-97
14. Cadenas E. Antioxidant and prooxidant functions of DTdiaphorase in quinone metabolism. Biochem Pharmacol 1995;49: 127-40
15. Chou TC, Talalay P. Simple generalized equation for analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977;252:6438-42
16. Preusch PC, Siegel D, Gibson NW, Ross D. A note on the inhibition of DT-diaphorase by dicoumarol. Free Radic Biol Med 1991;11: 77-80
17. Faig M, Bianchet MA, Winski S, et al. Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. Structure 2001;9:659-67
18. Nolan KA, Timson DJ, Stratford IJ, Bryce RA. In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett 2006;16:6246-54
19. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DTdiaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-17
20. Srivastava M, Khurana P, Sugadev R. Lung cancer signature biomarkers: tissue specific semantic similarity based clustering of digital differential display (DDD) data. BMC Res Notes 2012;5: 617
21. Awadallah NS, Dehn D, Shah RJ, et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 2008;16:24-31
22. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998;4:2065-70
23. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 1990;45:403-9
24. Lewis AM, Ough M, Hinkhouse MM, et al. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 2005;43:215-24
25. DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-9
26. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1- NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3: e420
27. Cruz FS, Docampo R, Boveris A. Generation of superoxide anions and hydrogen peroxide from beta-lapachone in bacteria. Antimicrob Agents Chemother 1978;14:630-3
28. Boveris A, Docampo R, Turrens JF, Stoppani AO. Effect of betalapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi. Biochem J 1978;175:431-9
29. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by betalapachone, an activator of topoisomerase I. Cancer Res 1989;49: 605-12
30. Pink JJ, Planchon SM, Tagliarino C, et al. NAD(P)H:quinone oxidoreductase activity is the principal determinant of betalapachone cytotoxicity. J Biol Chem 2000;275:5416-24
31. Planchon SM, Pink JJ, Tagliarino C, et al. Beta-lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/ xip3. Exp Cell Res 2001;267:95-106
32. Li LS, Bey EA, Dong Y, et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of betalapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17: 275-85
33. Docampo R, Cruz FS, Boveris A, et al. Beta-lapachone enhancement of lipid peroxidation and superoxide anion and hydrogen peroxide formation by sarcoma 180 ascites tumor cells. Biochem Pharmacol 1979;28:723-8
34. Imlay JA, Chin SM, Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. Science 1988;240:640-2
35. Bentle MS, Reinicke KE, Dong Y, et al. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res 2007;67:6936-45
36. Haince JF, McDonald D, Rodrigue A, et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 2008;283:1197-208
37. Beck C, Robert I, Reina-San-Martin B, et al. Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res 2014;329:18-25
38. Bey EA, Bentle MS, Reinicke KE, et al. An NQO1- and PARP-1- mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci USA 2007;104: 11832-7
39. Tagliarino C, Pink JJ, Dubyak GR, et al. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 2001; 276:19150-9
40. Pink JJ, Wuerzberger-Davis S, Tagliarino C, et al. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis. Exp Cell Res 2000;255: 144-55
41. Tagliarino C, Pink JJ, Reinicke KE, et al. Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther 2003;2: 141-52
42. Bey EA, Reinicke KE, Srougi MC, et al. Catalase abrogates betalapachone- induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther 2013; 12:2110-20
43. Park EJ, Min KJ, Lee TJ, et al. Beta-lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis 2014;5:e1230
44. Bentle MS, Reinicke KE, Bey EA, et al. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 2006;281: 33684-96
45. Huang X, Dong Y, Bey EA, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 2012;72:3038-47
46. van Wijk SJ, Hageman GJ. Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. Free Radic Biol Med 2005;39:81-90
47. Ying W, Sevigny MB, Chen Y, Swanson RA. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death. Proc Natl Acad Sci USA 2001;98:12227-32
48. Woo HJ, Choi YH. Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity. Int J Oncol 2005;26: 1017-23
49. Park MT, Song MJ, Lee H, et al. Beta-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells. PLoS One 2011;6: e25976
50. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998;98:1743-54
51. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35
52. Nasongkla N, Wiedmann A, Bruening A, et al. Enhancement of solubility and bioavailability of b-lapachone using cyclodextrin inclusion complexes. Pharm Res 2003;20:1626-33
53. Hartner PL Rosen L, Hensley M, et al. Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS). J Clin Oncol 2007;25:20521
54. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos- Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003;100:6039-44
55. Jones M-C, Leroux J-C. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48: 101-11
56. Savić R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003; 300:615-18
57. Reinicke KE, Bey EA, Bentle MS, et al. Development of betalapachone prodrugs for therapy against human cancer cells withelevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res 2005;11:3055-64
58. Ma X, Huang X, Huang G, et al. Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of b-lapachone. Adv Healthcare Mater 2014;3: 1210-16
59. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7: 255-70
60. Perez C, Daniel KB, Cohen SM. Evaluating prodrug strategies for esterase-triggered release of alcohols. ChemMedChem 2013;8: 1662-7
61. Hooker SC. The constitution of lapachol and its derivatives. Part IV.1 Oxidation with potassium permanganate2,3. J Am Chem Soc 1936;58:1168-73
62. Xu G, Zhang W, Ma MK, McLeod HL. Human Carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-11
63. Lu X, Howard MD, Talbert DR, et al. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J 2009;11: 120-2
64. Ma X, Huang X, Moore Z, et al. Esterase-activatable b-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. J Control Release 2015;200:201-11
65. Dong Y, Bey EA, Li L-S, et al. Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation. Cancer Res 2010;70:8088-96
66. Cenas N, Ollinger K. Redox conversions of methemoglobin during redox cycling of quinones and aromatic nitrocompounds. Arch Biochem Biophys 1994;315:170-6
67. Park HJ, Ahn KJ, Ahn SD, et al. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. Int J Radiat Oncol Biol Phys 2005;61:212-19
68. Reddy S, Li L, Boothman DA, et al. NQO1-mediated synergistic lethality in combination with b-lapachone (b-lap) and ionizing radiation (IR) in head-and-neck cancer (HNC). Int J Radiat Oncol Biol Phys 2013;87:S139
69. D'Anneo A, Augello G, Santulli A, et al. Paclitaxel and betalapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt. J Cell Physiol 2010;222:433-43
70. Terai K, Dong GZ, Oh ET, et al. Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anticancer Drugs 2009;20:901-9